Efficacy and safety of emodepside 2.1%/praziquantel 8.6% spot-on formulation in the treatment of feline aelurostrongylosis.
The objective of the present study was to evaluate the efficacy and safety of the antiparasitic spot-on formulation containing emodepside 2.1%/praziquantel 8.6% (Profender, Bayer) in the treatment of natural feline infection with the lungworm Aelurostrongylus abstrusus (Nematoda, Strongylida). Efficacy of Profender given once at the licensed dose was tested in comparison to a control oral formulation containing fenbendazole 18.75% (Panacur, Intervet) given over three consecutive days at the licensed dose. Efficacy assessment was based on larvae per gramme of faeces (LPG) counts, measured on days 28 +/- 2 following treatment and compared to counts on days -6 to -2. In total 24 cats treated either with Profender (n = 12) or with Panacur (n = 12) were included in the assessment of efficacy and safety. Mean LPG post-baseline counts (days 28 +/- 2) were 1.3 LPG for both Profender and Panacur, demonstrating similar efficacy of 99.38% for Profender and 99.29% for the control product. No treated animals showed adverse events. This trial demonstrated that both Profender spot-on formulation and oral paste Panacur are safe and effective in the treatment of aelurotrongylosis in cats. Future practical perspectives in feline medicine and the major advantages of the spot-on product compared to the oral paste are discussed.
Traversa
Donato
D
Department of Comparative Biomedical Sciences, Faculty of Veterinary Medicine, Teramo, Italy. dtraversa@unite.it
Milillo
Piermarino
P
Di Cesare
Angela
A
Lohr
Beate
B
Iorio
Raffaella
R
Pampurini
Fabrizio
F
Schaper
Roland
R
Bartolini
Roberto
R
Heine
Josef
J
D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002371:Cat Diseases / Q000188:drug therapy* / Q000469:parasitology; D002415:Cats; D047630:Depsipeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004338:Drug Combinations; D005243:Feces / Q000469:parasitology; D005273:Fenbendazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D007814:Larva / Q000187:drug effects; D008681:Metastrongyloidea / Q000187:drug effects / Q000302:isolation & purification; D011223:Praziquantel / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017206:Strongylida Infections / Q000188:drug therapy / Q000469:parasitology / Q000662:veterinary*; D016896:Treatment Outcome
D000871:Anthelmintics; D047630:Depsipeptides; D004338:Drug Combinations; D005273:Fenbendazole; D011223:Praziquantel; C468987:emodepside